Remimazolam vs Propofol in Laser Burn Cases

Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorMedical University of South Carolina

About this trial

This randomized, single-blind, crossover study compares remimazolam and propofol for monitored anesthetic care during fractional ablative CO₂ laser therapy for burn scars. The primary aim is to assess incidence of respiratory depression, defined as a need for advanced airway maneuvers (jaw thrust/chin lift, insertion of oral or nasal airway, or bag mask ventilation), and hypopnea (respiratory rate \< 8).

Eligibility criteria

Qualifiers

Age ≥ 18 years

Undergoing both outpatient Session #1 and Session #2 of fractional ablative CO2 laser therapy

Disqualifiers

History of previous fractional ablative laser therapy for burn scar

Procedure expected to last longer than 30 minutes

Allergy such as dextran 40 or contraindication to either of the study drugs

Pregnant and/or breastfeeding

Trial design

Treatments tested in this trial

  • Remimazolam besylate
  • Propofol

Treatment groups

136 Participants
are divided into 2 treatment groups